Nonadherence to GLP-1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors

Efrata A Shegena, Mekdes Kiflu, Muktar Ahmed, Akshaya Srikanth Bhagavathula, Tadesse M Abegaz

Published in

Obesity reviews : an official journal of the International Association for the Study of Obesity. Pages e70200. Jul 26, 2026. Epub Jul 26, 2026.

Abstract

Glucagon-like peptide 1 (GLP-1) agonists are widely used for obesity management in patients with or without diabetes. However, treatment persistence is often limited due to adverse drug reactions (ADRs). Understanding adherence patterns in randomized controlled trials (RCTs) is crucial for predicting real-world treatment acceptance.
To estimate the pooled nonadherence rates and reasons for nonadherence to GLP-1 agonists in overweight or patients with obesity participating in RCTs.
A systematic review and meta-analysis of RCTs was conducted to evaluate nonadherence to GLP-1 receptor agonists. A literature search was performed in PubMed, Embase, and Web of Science from inception to October 2, 2024. Studies were included if they evaluated GLP-1 receptor agonists for overweight or obesity management and reported adherence outcomes.
The pooled RR for nonadherence to GLP-1 receptor agonists was 0.63 (95% CI: 0.48, 0.82, p = 0.01), indicating a 37% lower risk of nonadherence compared with the control group. However, ADR-induced nonadherence was significantly higher in the GLP-1 group (RR: 2.29 [95% CI: 1.47, 3.56, p = 0.04]), particularly due to gastrointestinal side effects. Nonadherence due to loss to follow-up was lower in the GLP-1 group (RR: 0.43 [95% CI: 0.27, 0.71, p = 0.18]).
GLP-1 receptor agonists were associated with a lower overall nonadherence rate in RCTs compared with control treatments, suggesting higher persistence. However, ADR-related nonadherence was significantly higher, particularly due to gastrointestinal side effects. These findings highlight the need for strategies to improve treatment tolerability and adherence in real-world settings.

PMID:
42503568
Bibliographic data and abstract were imported from PubMed on 27 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.